Literature DB >> 23151019

An efficient and practical radiosynthesis of [11C]temozolomide.

Christian K Moseley1, Stephen M Carlin, Ramesh Neelamegam, Jacob M Hooker.   

Abstract

Temozolomide (TMZ) is a prodrug for an alkylating agent used for the treatment of malignant brain tumors. A positron emitting version, [(11)C]TMZ, has been utilized to help elucidate the mechanism and biodistribution of TMZ. Challenges in [(11)C]TMZ synthesis and reformulation make it difficult for routine production. A highly reproducible one-pot radiosynthesis of [(11)C]TMZ with a radiochemical yield of 17 ± 5% and ≥97% radiochemical purity is reported.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23151019      PMCID： PMC3979304          DOI： 10.1021/ol302791x

Source DB:  PubMed          Journal:  Org Lett        ISSN： 1523-7052            Impact factor:   6.005


  10 in total

Review 1.  Chemical approaches to the discovery and development of cancer therapies.

Authors:  Stephen Neidle; David E Thurston
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

2.  Brain tumor survival: results from the National Cancer Data Base.

Authors:  T S Surawicz; F Davis; S Freels; E R Laws; H R Menck
Journal:  J Neurooncol       Date:  1998-11       Impact factor: 4.130

3.  A review of dose-dense temozolomide alone and in combination with bevacizumab in patients with first relapse of glioblastoma.

Authors:  Fredrik Johansson; Simon Ekman; Erik Blomquist; Roger Henriksson; Stefan Bergström; Michael Bergqvist
Journal:  Anticancer Res       Date:  2012-09       Impact factor: 2.480

4.  Two routes to [11C-carbonyl]organo-isocyanates utilizing [11C]phosgene ([11C]organo-isocyanates from [11C]phosgene).

Authors:  G D Brown; D Henderson; C Steel; S Luthra; P M Price; F Brady
Journal:  Nucl Med Biol       Date:  2001-11       Impact factor: 2.408

5.  Antitumor imidazotetrazines. 40. Radiosyntheses of [4-11C-carbonyl]- and [3-N-11C-methyl]-8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (temozolomide) for positron emission tomography (PET) studies.

Authors:  Gavin D Brown; Sajinder K Luthra; Cathryn S Brock; Malcolm F G Stevens; Patricia M Price; Frank Brady
Journal:  J Med Chem       Date:  2002-12-05       Impact factor: 7.446

Review 6.  Temozolomide and treatment of malignant glioma.

Authors:  H S Friedman; T Kerby; H Calvert
Journal:  Clin Cancer Res       Date:  2000-07       Impact factor: 12.531

7.  Antitumor Imidazotetrazines. 35. New Synthetic Routes to the Antitumor Drug Temozolomide.

Authors:  Yongfeng Wang; Malcolm F. G. Stevens; Donald DiBenedetto; Dinesh Gala; Donald Hou; Max Kugelman; William Leong; Janet L. Mas; Doris P. Schumacher; Bruce P. Shutts; Lyman Smith; Zheng-Yun J. Zhan; William T. Thomson
Journal:  J Org Chem       Date:  1997-10-17       Impact factor: 4.354

8.  Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent.

Authors:  M F Stevens; J A Hickman; R Stone; N W Gibson; G U Baig; E Lunt; C G Newton
Journal:  J Med Chem       Date:  1984-02       Impact factor: 7.446

9.  NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA.

Authors:  B J Denny; R T Wheelhouse; M F Stevens; L L Tsang; J A Slack
Journal:  Biochemistry       Date:  1994-08-09       Impact factor: 3.162

10.  Metabolic activation of temozolomide measured in vivo using positron emission tomography.

Authors:  Azeem Saleem; Gavin D Brown; Frank Brady; Eric O Aboagye; Safiye Osman; Sajinder K Luthra; Alex S O Ranicar; Cathryn S Brock; Malcolm F G Stevens; Edward Newlands; Terry Jones; Pat Price
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701
  10 in total
  8 in total

1.  Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma.

Authors:  Elizabeth R Gerstner; Kyrre E Emblem; Ken Chang; Bella Vakulenko-Lagun; Yi-Fen Yen; Andrew L Beers; Jorg Dietrich; Scott R Plotkin; Ciprian Catana; Jacob M Hooker; Dan G Duda; Bruce Rosen; Jayashree Kalpathy-Cramer; Rakesh K Jain; Tracy Batchelor
Journal:  Clin Cancer Res       Date:  2019-09-26       Impact factor: 12.531

2.  Multimodality imaging and mathematical modelling of drug delivery to glioblastomas.

Authors:  Ahmed Boujelben; Michael Watson; Steven McDougall; Yi-Fen Yen; Elizabeth R Gerstner; Ciprian Catana; Thomas Deisboeck; Tracy T Batchelor; David Boas; Bruce Rosen; Jayashree Kalpathy-Cramer; Mark A J Chaplain
Journal:  Interface Focus       Date:  2016-10-06       Impact factor: 3.906

Review 3.  Principles of Simultaneous PET/MR Imaging.

Authors:  Ciprian Catana
Journal:  Magn Reson Imaging Clin N Am       Date:  2017-05       Impact factor: 2.266

4.  Model studies towards prodrugs of the glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON) containing a diazo precursor.

Authors:  Run-Duo Gao; Niyada Hin; Eva Prchalová; Arindom Pal; Jenny Lam; Rana Rais; Barbara S Slusher; Takashi Tsukamoto
Journal:  Bioorg Med Chem Lett       Date:  2021-08-13       Impact factor: 2.940

5.  Arterial Spin Labeling and Dynamic Susceptibility Contrast-enhanced MR Imaging for evaluation of arteriovenous shunting and tumor hypoxia in glioblastoma.

Authors:  S Ali Nabavizadeh; Hamed Akbari; Jeffrey B Ware; MacLean Nasrallah; Samantha Guiry; Stephen J Bagley; Arati Desai; Scott Levy; Whitney Sarchiapone; Timothy Prior; John Detre; Ronald L Wolf; Donald M O'Rourke; Steven Brem; Christos Davatzikos
Journal:  Sci Rep       Date:  2019-06-19       Impact factor: 4.379

6.  Enhanced blood-brain-barrier penetrability and tumor-targeting efficiency by peptide-functionalized poly(amidoamine) dendrimer for the therapy of gliomas.

Authors:  Changliang Liu; Zijian Zhao; Houqian Gao; Iman Rostami; Qing You; Xinru Jia; Chen Wang; Ling Zhu; Yanlian Yang
Journal:  Nanotheranostics       Date:  2019-09-19

7.  The medicinal chemistry of imidazotetrazine prodrugs.

Authors:  Catherine L Moody; Richard T Wheelhouse
Journal:  Pharmaceuticals (Basel)       Date:  2014-07-10

8.  Tunable Stability of Imidazotetrazines Leads to a Potent Compound for Glioblastoma.

Authors:  Riley L Svec; Lucia Furiassi; Christine G Skibinski; Timothy M Fan; Gregory J Riggins; Paul J Hergenrother
Journal:  ACS Chem Biol       Date:  2018-11-08       Impact factor: 5.100
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.